Diabetes is a chronic condition affecting over 30 million individuals in the US, making it an incredibly prevalent disease. Its effects can be widespread and sometimes fatal, leading to cardiovascular, nerve, eye, ear, and oral complications down the line if left untreated.

Diabetes can be a demanding condition, with many individuals needing to take daily medication and insulin several times a day to manage their blood sugar levels. Thankfully, treatment options for diabetic patients are expanding, with new and effective therapies hitting the market. One such medication is Mounjaro. Reach on to find out how patients in the US can order mounjaro from Canada online from $158.99 per vial.

What is Mounjaro?

In May 2022, Mounjaro (tirzepatide) was approved by the Food and Drug Administration (FDA) to manage blood sugar in adult individuals with type 2 diabetes as an adjunct to diet and exercise. More recently, Mounjaro’s active ingredient tirzepatide was approved under a different brand name for weight loss management. Its dual mechanism has led to significantly positive results in clinical trials, making it a great option for diabetic, overweight, and obese individuals to better their health and wellness.

Common diabetes and weight loss drugs that you may have heard of, like Ozempic (semaglutide), belong to a class of drugs known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists function in diabetes through their action on insulin release. Recall that in type 2 diabetes, individuals may not make enough insulin or become insulin resistant, blunting their insulin response, thereby allowing blood sugar levels to remain high. As a GLP-1 agonist, tirzepatide activates the release of insulin from the pancreas, thus helping to regulate blood sugar levels by bringing those levels down. Additionally, GLP-1 agonists prevent the death of beta cells in the pancreas while also promoting the growth of new beta cells.

Tirzepatide belongs to this class of medications known as GLP-1 agonists, supporting its use case in type 2 diabetes. However, tirzepatide is unique from other GLP-1 agonists because of its additional mechanism as a glucose-dependent insulinotropic polypeptide (GIP) agonist. Like GLP-1s, GIP agonists promote pancreatic insulin release, helping maintain normal blood sugar levels. They also function similarly in that they promote the growth and development of pancreatic beta cells and prevent the death of these cells, enhancing the body’s response to glucose.

Through this dual mechanism, acting on GLP-1 and GIP receptors, tirzepatide induces potent effects on blood sugar levels in diabetic patients. Likewise, it has demonstrated robust efficacy and safety results in clinical trials, leading to its approval as a new antidiabetic modality.

How does Mounjaro help with diabetes?

While we now know the pathophysiological mechanisms that underly Mounjaro’s efficacy, how exactly did this drug measure up in clinical trials? Five different studies evaluated Mounjaro across several doses (5, 10, and 15 mg), helping to characterize Mounjaro’s safety and efficacy profile over several years of clinical investigations. These SURPASS studies were developed as follows:

  • SURPASS-1: Mounjaro as monotherapy
  • SURPASS-2, -3, and -4: Mounjaro in addition to metformin sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors), and sulfonylureas
  • SURPASS-5: Mounjaro together with basal insulin with or without metformin

Given that Mounjaro was evaluated across a wide array of antidiabetic regimens within these five trials, the results of these studies can help to inform how it might help most diabetic patients. Let’s review exactly how Mounjaro can treat diabetes in each of these patient populations.


SURPASS-1 was a 40-week double-blind study that included 478 adult individuals with uncontrolled type 2 diabetes despite diet and exercise interventions. Participants were randomized to receive either a placebo or 5, 10, or 15 mg of Mounjaro once a week. In terms of patient population, the average age was 54 years old, and 52 percent of participants were men.

Results indicated that taking Mounjaro as monotherapy (alone without other pharmacologic antidiabetic treatment) yielded statistically significant decreases in participant’s hemoglobin A1C (HbA1c) when treated with Mounjaro versus placebo. This effect was consistent across all three doses of Mounjaro.

Results indicated that reductions in HbA1c were 0.1, 1.8, 1.7, and 1.7 percent for placebo, Mounjaro 5 mg, Mounjaro 10 mg, and Mounjaro 15 mg, respectively. Additionally, the percentage of participants achieving an HbA1c level below seven percent were 23, 82, 85, and 78 percent for placebo, Mounjaro 5 mg, Mounjaro 10 mg, and Mounjaro 15 mg, respectively. Likewise, Mounjaro was effective at all doses, even the lowest dose of 5 mg studied.


SURPASS-2 was another 40-week study, although this time it was open-label although double-blind when it came to Mounjaro dose assignment. A total of 1,879 patients with uncontrolled type 2 diabetes on metformin were randomized to receive either semaglutide or Mounjaro at one of its three doses.

At week 40, Mounjaro treatment with 10 and 15 mg doses yielded a statistically significant decrease in HbA1c versus a once-weekly injection of semaglutide 1 mg. The difference in HbA1c reductions from semaglutide were 0.2, 0.4, and 0.5 percent for Mounjaro 5, 10, and 15 mg, respectively. Additionally, individuals achieving an HbA1c level of less than seven percent were 79, 82, 86, and 86 percent of participants in the semaglutide, Mounjaro 5 mg, Mounjaro 10 mg, and Mounjaro 15 mg dose cohorts.


SURPASS-3 was an open-label study lasting 52 weeks which randomized 1,444 participants with uncontrolled diabetes. These patients had to be on metformin with or without an SGLT-2 inhibitor. On top of this regimen, participants were randomized to receive either insulin degludec or Mounjaro at a dose of 5, 10, or 15 mg.

Compared with insulin degludec, Mounjaro induced statistically significant decreases in HbA1c at doses of 10 and 15 mg. In terms of the difference in HbA1c levels versus degludec, Mounjaro provided an additional 0.6, 0.8, and 0.9 percent decrease in the 5 mg, 10 mg, and 15 mg groups, respectively. The percentage of patients achieving an HbA1c of less than seven percent were 58, 79, 82, and 83 percent for insulin degludec, Mounjaro 5 mg, Mounjaro 10 mg, and Mounjaro 15 mg, respectively.


The next trial lasted 104 weeks, randomizing 2,002 type 2 diabetic patients with elevated cardiovascular risk to either insulin glargine or Mounjaro. Individuals had to be on background treatment of metformin and/or sulfonylureas and/or SGLT-2 inhibitors. Results indicated that Mounjaro 10 and 15 mg doses provided statistically significant decreases in HbA1c versus insulin glargine-treated patients.


The final 40-week double-blind study enrolled 475 individuals with uncontrolled type 2 diabetes on insulin glargine with or without metformin. Patients were then treated on top of this background regimen with either Mounjaro or a placebo. Treatment with all three doses of Mounjaro induced statistically significant decreases in HbA1c versus placebo.

Comparison with Other Diabetes Medications

Mounjaro (tirzepatide) represents a significant advancement in diabetes treatment, particularly when compared to traditional medications like Metformin, Sulfonylureas, and DPP-4 inhibitors. Each of these medications operates through different mechanisms, offering varied benefits and drawbacks.

Metformin, often the first line of treatment for type 2 diabetes, works by reducing glucose production in the liver and improving insulin sensitivity. It’s known for its effectiveness, safety profile, and the added benefit of not causing weight gain, which is crucial for diabetic patients. However, it may not be sufficient alone for long-term blood sugar control.

Sulfonylureas, another class of diabetes medications, stimulates the pancreas to produce more insulin. While effective in lowering blood glucose levels, they carry a risk of hypoglycemia (low blood sugar) and may contribute to weight gain, which can be a concern for many patients.

DPP-4 inhibitors, a newer class of drugs, work by blocking the enzyme DPP-4, enhancing the body’s ability to lower elevated blood sugar levels, especially after meals. They are less likely to cause hypoglycemia but are generally considered less effective than other options in reducing blood sugar levels.

Mounjaro, with its dual mechanism as both a GLP-1 and GIP agonist, not only stimulates insulin release but also slows gastric emptying and reduces appetite. This dual action can lead to significant improvements in blood sugar control and weight loss, a major advantage over other medications. However, it may have gastrointestinal side effects and require subcutaneous administration, which might be a drawback for some patients.

While traditional medications like Metformin, Sulfonylureas, and DPP-4 inhibitors have their place in diabetes management, Mounjaro offers a unique combination of blood sugar control and potential weight loss, positioning it as a valuable option for many patients with type 2 diabetes.

What about side effects?

It’s no secret from the aforementioned results that Mounjaro provides potent efficacy in the realm of type 2 diabetes, even more so than some traditional antidiabetic agents. But it is also important to know its safety profile, and what kinds of side effects and adverse events may have been observed in these studies.

The most common side effects reported, occurring in at least five percent of patients, were nausea, vomiting, diarrhea, constipation, indigestion, low appetite, and stomach pain. Other warnings associated with Mounjaro use included pancreatitis, allergy, low blood sugar, serious gastrointestinal (GI) disease, diabetic retinopathy complications, acute gallbladder disease, and acute kidney injury. These risks are important to be aware of before starting therapy and something that you should discuss with your doctor.

What else can Mounjaro do?

While Mounjaro is certainly efficacious for type 2 diabetes, it also has demonstrated positive benefits in other conditions. In particular, Mounjaro’s active ingredient tirzepatide is very effective in inducing weight loss in overweight or obese patients. Just recently in November, tirzepatide was approved under the brand name Zepbound for chronic weight management for obese or overweight adults with at least one weight-associated condition. Although Zepbound contains the same active ingredient as Mounjaro, it is recommended at a different dose for this indication.

In clinical trials, tirzepatide was evaluated at 5, 10, and 15 mg doses over 72 weeks. One of the trials enrolled non-diabetic patients, while one of the trials enrolled diabetic patients. Between the two trials, individuals receiving the highest dose of tirzepatide (15 mg) lost an average of 12 to 18 percent of their body weight.

A consequent effect of weight loss is blood pressure. The SURPASS trials also demonstrated that tirzepatide was associated with decreases in systolic blood pressure (SBP). SBP decreased by 12.6 mmHg after 42 weeks of treatment. These effects are likely a downstream effect of the weight loss induced by tirzepatide.

Dietary and Lifestyle Recommendations for Type 2 Diabetics

Effective management of type 2 diabetes involves more than just medication; it encompasses a comprehensive approach that includes significant dietary and lifestyle modifications. For individuals living with type 2 diabetes, making informed choices about their diet and daily habits is essential for maintaining stable blood sugar levels and overall health.

Dietary Guidelines:

  • Balanced Meals: Focus on a diet rich in vegetables, fruits, whole grains, lean proteins, and healthy fats. This balance helps in regulating blood sugar levels.
  • Fiber-rich foods: Incorporate plenty of fiber through vegetables, fruits, legumes, and whole grains. Fiber aids in slowing down glucose absorption, thereby stabilizing blood sugar.
  • Healthy Proteins: Opt for lean protein sources like poultry, fish, tofu, and legumes. These provide essential nutrients without excessive saturated fats.
  • Controlled Carbohydrate Intake: Be mindful of carbohydrate consumption, as it has the most direct impact on blood sugar. Choose complex carbohydrates over simple sugars.
  • Limit Processed Foods: Reduce intake of processed and high-sugar foods to avoid blood sugar spikes.

Lifestyle Adjustments:

  • Regular Physical Activity: Engage in at least 150 minutes of moderate-intensity exercise per week, such as walking, swimming, or cycling.
  • Weight Management: Strive for a healthy weight, as weight loss can enhance insulin sensitivity and reduce the risk of complications.
  • Stress Reduction: Practice stress-relieving activities like meditation, yoga, or deep breathing exercises.
  • Adequate Sleep: Ensure sufficient and quality sleep, as poor sleep can affect blood sugar control.

By adopting these dietary and lifestyle changes, individuals with type 2 diabetes can significantly improve their glycemic control and overall health, reducing the risk of complications associated with the condition.

Future Developments in Diabetes Treatment

The landscape of diabetes treatment is rapidly evolving, with ongoing research paving the way for innovative therapies. Future developments are focusing on more personalized medicine, leveraging advancements in technology and pharmacology. Researchers are exploring novel drug classes that target different aspects of diabetes pathology, potentially offering more effective and tailored treatment options. Additionally, there’s a growing emphasis on non-invasive glucose monitoring systems and insulin delivery methods, enhancing patient convenience and compliance. Mounjaro, with its unique dual-action mechanism, represents a significant step in this direction, offering a glimpse into the future of diabetes care where treatments are not only more effective but also more aligned with individual patient needs. As research continues, we can expect to see more groundbreaking therapies that offer improved glycemic control and better quality of life for those living with diabetes.

Making Mounjaro as effective as possible

It is important to note that Mounjaro is approved for the treatment of diabetes in addition to diet and exercise. If you want to maximize the effects of Mounjaro to optimize your blood sugar control, you should ensure you are instilling healthy lifestyle habits. This includes eating a nutritious, well-balanced diet and engaging in at least 150 minutes of aerobic exercise weekly.

Cost Comparison of Mounjaro: United States vs. Canada

Cost of Mounjaro in the United States

In the United States, the price for Mounjaro subcutaneous solution (2.5 mg/0.5 mL) is approximately $1,087 for a supply of 2 milliliters, based on the information from Drugs.com. This equates to around $543.38 per milliliter. This price is for cash-paying customers and does not account for insurance coverage. It’s important to note that prices may vary depending on the pharmacy and available discounts or savings programs.

Cost of Mounjaro at BuyCanadianInsulin.com

On Buy Canadian Insulin, Americans can order Mounjaro from Canada at significantly lower prices, starting from $158.99 per vial. They also provide bulk purchase discounts, which are as follows:

  • 1 Vial: $158.99
  • 2 Vials: $317.98
  • 3 Vials: $467.97
  • 4 Vials: $623.96

This pricing structure indicates that the cost per vial decreases slightly with the purchase of four vials, averaging approximately $156 per vial. Customers are limited to a 90-day supply per order, in line with standard medication dispensing regulations.

Comparing these prices, it’s evident that Mounjaro is available at a significantly lower cost at BuyCanadianInsulin.com compared to the average US retail price. This price difference can be a crucial factor for patients considering cost-effective options for their diabetes management. However, patients should always consult with their healthcare providers and consider factors like insurance coverage, shipping, and reliability of the source when making decisions about where to purchase their medications.

Key Takeaways

Here are 10 key takeaways from the article “How Mounjaro Aids Type 2 Diabetics”:

  • Prevalence of Diabetes: Over 30 million individuals in the US are affected by diabetes, highlighting its widespread impact on health.
  • Complexity of Diabetes Management: Managing diabetes often requires daily medication and insulin, underscoring the need for effective treatment options.
  • Introduction of Mounjaro: Mounjaro (tirzepatide), approved in May 2022 by the FDA, represents a significant advancement in diabetes treatment.
  • Dual Mechanism of Mounjaro: Mounjaro’s active ingredient, tirzepatide, functions as both a GLP-1 and GIP agonist, offering a unique approach to managing blood sugar levels.
  • Clinical Trial Success: Mounjaro has shown positive results in clinical trials, demonstrating its efficacy in blood sugar regulation and safety for patients.
  • Comparison with Other Medications: Mounjaro’s dual-action mechanism distinguishes it from other diabetes medications like Metformin, Sulfonylureas, and DPP-4 inhibitors.
  • Potential Side Effects: Common side effects of Mounjaro include gastrointestinal issues, with other potential risks that patients should discuss with their healthcare providers.
  • Weight Loss Benefits: Mounjaro’s active ingredient is also effective in weight loss management, making it beneficial for overweight or obese diabetic patients.
  • Importance of Lifestyle Changes: Alongside medication, dietary and lifestyle modifications are crucial for effective diabetes management.
  • Cost Comparison: Mounjaro’s cost varies significantly between the US market and Canadian suppliers, with BuyCanadianInsulin.com offering it at a much lower price, highlighting the importance of cost considerations in treatment choices.